More Encouraging Data For Moderna And Merck & Co’s Personalized Cancer Therapy

A therapy individualized to each patient’s cancer has produced encouraging three-year data – though talk of accelerated approval remains a moot point.

Merck 1200

Confidence in Moderna and Merck & Co.'s novel individualized neoantigen therapy (INT) combination with Keytruda has grown after the companies unveiled new three-year data in melanoma patients.

The candidate mRNA-4157 (V940) is a potential first-in-class INT which is important for Merck as it looks to extend its dominance in cancer immunotherapy and vital for Moderna as it seeks

Key Takeaways
  • Moderna and Merck believe they can be first with a neoantigen-based cancer immunotherapy

  • The updated Phase II results confirm its advantages over Keytruda monotherapy after three years

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Takeda Plans US Investment But Sees Little Impact From Tariffs

 

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.